Is BCG vaccination against tuberculosis still indicated?

Area of Science:

• Immunology
• Infectious Diseases
• Public Health

Background:

• Bacille Calmette-Guérin (BCG) vaccination has been used for over 70 years, but its efficacy against tuberculosis remains debated.
• Major clinical trials have yielded conflicting results regarding the protective benefits of BCG vaccination.
• Factors contributing to these inconsistent trial outcomes are explored.

Purpose of the Study:

• To review the current understanding of BCG vaccination's effectiveness against tuberculosis.
• To discuss the relevance of BCG vaccination in both developing and developed countries.
• To re-evaluate the role of BCG vaccination in specific high-risk populations, including healthcare workers.

Main Methods:

• Literature review of major BCG vaccination trials.
• Analysis of tuberculosis incidence trends in different global regions.
• Discussion of BCG vaccination's applicability based on tuberculosis prevalence and risk factors.

Main Results:

• BCG vaccination is recommended for infants in developing countries due to ease of administration, low cost, safety, and protection against disseminated tuberculosis.
• In developed countries, BCG is typically reserved for high-risk groups, but rising tuberculosis incidence warrants reconsideration.
• BCG vaccination is considered a valuable preventive measure for healthcare workers, particularly in areas with high rates of multidrug-resistant tuberculosis.

Conclusions:

• BCG vaccination remains a relevant tool in tuberculosis control, especially in resource-limited settings.
• Re-emergence of tuberculosis necessitates a renewed focus on preventive strategies, including BCG vaccination for specific populations in developed countries.
• BCG vaccination continues to hold a future in global tuberculosis prevention efforts.